Presentation Information
GLP-1 Medications During Lactation: Pharmacology, Practicalities, and Shared Decisions
- Speaker: Treasure McGuire , PhD, BSc, BPharm, GradDipClinHospPharm Adv Prac Pharm, GCHEd, CertIVTAE, FACP, FPS
- Presentation Type:
- Duration: 60 Mins
- Credits:
Abstract:
The media attention and rapid uptake of GLP-1 receptor agonists (GLP-1 RAs) such as semaglutide, liraglutide, and dulaglutide, for diabetes and obesity management, has created new clinical questions for postpartum care, particularly regarding safety during breastfeeding. Many individuals resume or initiate GLP-1 RA therapy soon after birth, yet clinicians lack clear, mechanistic, and evidence-based guidance to support decision making.
This presentation provides a clinically grounded review of how GLP-1 RAs behave in lactating patients, focusing on pharmacokinetic determinants of drug transfer into breast milk - including molecular size, protein binding, half-life, and maternal plasma concentrations - and the expected oral bioavailability and degradation of these peptide-based medicines in the infant gastrointestinal tract. Available human milk sampling data, infant exposure modelling, and real-world postpartum outcomes are reviewed to clarify what is known, what remains theoretical, and where caution is warranted. Maternal considerations such as glycaemic control, nutritional adequacy, gastrointestinal tolerability, hydration, and weight trajectory are discussed in relation to lactation physiology and milk supply.
The session equips clinicians with practical, mechanism informed frameworks to evaluate risk, counsel breastfeeding patients, and make shared decisions about initiating, continuing, or pausing GLP-1 RA therapy in the postpartum period.
Live Presentation Schedule
Apr 27, 2027
-
Create a Reminder
27-04-2027 21:00
27-04-2027 22:00
35
GLP-1 Medications During Lactation: Pharmacology, Practicalities, and Shared Decisions
The media attention and rapid uptake of GLP-1 receptor agonists (GLP-1 RAs) such as semaglutide, liraglutide, and dulaglutide, for diabetes and obesity management, has created new clinical questions for postpartum care, particularly regarding safety during breastfeeding. Many individuals resume or initiate GLP-1 RA therapy soon after birth, yet clinicians lack clear, mechanistic, and evidence-based guidance to support decision making. This presentation provides a clinically grounded review of how GLP-1 RAs behave in lactating patients, focusing on pharmacokinetic determinants of drug transfer into breast milk - including molecular size, protein binding, half-life, and maternal plasma concentrations - and the expected oral bioavailability and degradation of these peptide-based medicines in the infant gastrointestinal tract. Available human milk sampling data, infant exposure modelling, and real-world postpartum outcomes are reviewed to clarify what is known, what remains theoretical, and where caution is warranted. Maternal considerations such as glycaemic control, nutritional adequacy, gastrointestinal tolerability, hydration, and weight trajectory are discussed in relation to lactation physiology and milk supply. The session equips clinicians with practical, mechanism informed frameworks to evaluate risk, counsel breastfeeding patients, and make shared decisions about initiating, continuing, or pausing GLP-1 RA therapy in the postpartum period.
GOLD Lactation Conference
false
DD/MM/YYYY
-
Tell a Friend

